2011 Press Releases
December 8
Media Advisory: QLT to Host Research and Development Day in New York City on December 16, 2011
PDF Format
November 3
QLT Announces Third Quarter Results for 2011
October 26
Media Advisory: QLT to Report Third Quarter Financial Results on November 3, 2011
September 19
QLT to Present at the UBS Global Life Sciences Conference
September 14
QLT Receives Fast Track Designation for QLT091001 to Treat Both Leber Congenital Amaurosis and Retinitis Pigmentosa
August 29
QLT Shows Positive 4 Week Efficacy in Phase II Study for Glaucoma Using Latanoprost Punctal Plug Delivery System
July 28
QLT Announces Second Quarter Results for 2011
May 31
QLT Announces Issuance of U.S. Patent for Use of QLT091001 in Treatment of Inherited or Age-Related Retinal Diseases
May 05
QLT Announces First Quarter Results for 2011
May 03
QLT Announces Positive Results from Phase 1b Trial of QLT091001 in Subjects with Leber Congenital Amaurosis
April 27
QLT Announces QLT091001 Presentation at ARVO
March 01
QLT Announces Fourth Quarter and Year End 2010 Results
February 23
QLT Chief Medical Officer Steps Down
February 10
QLT Receives Positive Opinions for Orphan Drug Designation by the European Medical Agency for QLT091001 to Treat Two Hereditary Blindness Diseases
February 09
QLT Announces Phase II Clinical Trial Results for the Olopatadine Punctal Plug Delivery System (O-PPDS)
